Loading patent…
OwnerCinar Resat, Muhammad Arif +2inventors
InventorsCinar Resat, Muhammad Arif, Abhishek Basu, Malliga R. Iyer
Estimating the term…
The disclosure describes methods and compositions for reducing the level or activity of metabotropic glutamate receptor 5 (mGluR5) or/and cannabinoid receptor 1 (CB1R) for the treatment of fibrotic disorders such as pulmonary fibrotic disorders (e.g., fibrosing interstitial lung discases). In some embodiments, a mGluR5 antagonist or/and a CB1R antagonist (c.g., a peripheral CB1R antagonist) is/are used to treat a fibrotic disorder such as a pulmonary fibrotic disorder (e.g., a fibrosing interstitial lung disease).
A method for reducing fibrosis in a pulmonary fibrotic disease in a subject, comprising decreasing fibroproliferative activity at a fibrotic lesion in the subject by reducing the activity of metabotropic glutamate receptor 5 (mGluR5).
A method for treating a fibrotic disease in a subject, comprising administering to the subject in need of treatment a therapeutically effective amount of an antagonist of mGluR5 in combination with a therapeutically effective amount of an antagonist of CB1R, wherein the mGluR5 antagonist is a negative allosteric modulator of mGluR5 glutamate signaling or a selective mGluR5 activation inhibitor, and wherein the CB1R antagonist is a peripheral CB1R antagonist, or a pharmaceutically acceptable salt, polymorph, isomer, or prodrug thereof.
A pharmaceutical composition comprising:
Dependencies are inferred from the claim text.